Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PS1 in Healthy Subjects and Type II Diabetes Mellitus Patients
NCT05176210Phase 1Completed
- Sponsor
- Pharmasaga Co. Ltd.
- Start
- Dec 2023
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PS1 in type 2 diabetes mellitus (T2DM) (8 cohorts), sponsored by Pharmasaga Co. Ltd. Primary endpoints: Dose-Limiting Toxicity at Day 35 and Maximum Tolerated Dose at Day 35. Started Dec 2023; status: completed.
02
Drugs
PS1
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05176210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05176210.